Ritholtz Wealth Management Raises Stake in LifeVantage Co. (NASDAQ:LFVN)

Ritholtz Wealth Management lifted its position in LifeVantage Co. (NASDAQ:LFVN) by 65.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 47,348 shares of the company’s stock after purchasing an additional 18,682 shares during the period. Ritholtz Wealth Management’s holdings in LifeVantage were worth $830,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Barclays PLC lifted its holdings in shares of LifeVantage by 38.2% in the third quarter. Barclays PLC now owns 41,966 shares of the company’s stock worth $507,000 after buying an additional 11,608 shares in the last quarter. HighTower Advisors LLC purchased a new stake in LifeVantage in the 3rd quarter worth $638,000. Capital Management Corp VA bought a new position in shares of LifeVantage during the 3rd quarter valued at about $5,073,000. Finally, Renaissance Technologies LLC grew its position in shares of LifeVantage by 2.1% during the second quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after purchasing an additional 17,300 shares in the last quarter. 35.32% of the stock is currently owned by institutional investors.

LifeVantage Price Performance

Shares of NASDAQ LFVN opened at $25.31 on Monday. The stock has a market capitalization of $316.88 million, a P/E ratio of 79.10 and a beta of 0.82. LifeVantage Co. has a 1-year low of $5.22 and a 1-year high of $27.38. The business’s 50 day moving average is $16.74 and its two-hundred day moving average is $12.16.

LifeVantage (NASDAQ:LFVN) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.15. LifeVantage had a return on equity of 29.24% and a net margin of 2.11%. The company had revenue of $47.21 million during the quarter.

LifeVantage Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were paid a $0.04 dividend. This represents a $0.16 annualized dividend and a yield of 0.63%. The ex-dividend date of this dividend was Monday, December 2nd. LifeVantage’s dividend payout ratio is presently 50.00%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LFVN. Lake Street Capital initiated coverage on LifeVantage in a report on Thursday, December 19th. They set a “buy” rating and a $26.00 price target for the company. Craig Hallum started coverage on shares of LifeVantage in a report on Tuesday, January 14th. They issued a “buy” rating and a $35.00 target price for the company.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.